Gene therapy and neurology specialist Voyager Therapeutics has appointed Jacquelyn Fahey Sandell as chief legal officer.
Ms Fahey Sandell has more than 25 years of legal experience in the biotech and pharmaceutical sectors, most recently as CLO at Jounce Therapeutics.
Voyager is working on the development of innovative medicines using its TRACER AAV capsid discovery platform.
The company aims to achieve high target delivery and blood-brain barrier penetration at low doses, with the goal of addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze